Is CPRX or CRVS more undervalued in 2026?

CirclFi compares Catalyst Pharmaceuticals, Inc. (CPRX) and Corvus Pharmaceuticals, Inc. (CRVS) using 13 institutional-grade valuation models. CPRX has a Quality of Company score of 10.0/10 while CRVS scores 4.6/10.

Which is a better buy — CPRX or CRVS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CPRX and CRVS valuations compare?

CPRX at $31.23 and CRVS at $12.41 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CPRX vs CRVS Valuation Comparison 2026 — Intrinsic Value Analysis

CPRX

Pharmaceutical Preparations

Catalyst Pharmaceuticals, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$31.23

Last close

Models

13/13

Active

CRVS

Pharmaceutical Preparations

Corvus Pharmaceuticals, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$12.41

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	CPRX Fair Value	CPRX Upside	CRVS Fair Value	CRVS Upside
Bayesian DCF	Intrinsic	$31.62	+1.2%	$3.63	-70.7%
Earnings Power Value	Intrinsic	$18.57	-40.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$41.43	+32.7%	$0.51	-96.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CPRX vs CRVS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CPRX vs CRVS — Which Stock Is More Undervalued?

CPRX scores higher with a 10.0/10 quality rating vs CRVS's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Catalyst Pharmaceuticals, Inc. (CPRX) and Corvus Pharmaceuticals, Inc. (CRVS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CPRX currently trades at $31.23 with a QOC of 10.0/10, while CRVS trades at $12.41 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).